/compare — side-by-sideLOADING

compare stocks // side-by-side, from filings

Compare any stocks, on the real numbers

Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.

Metric	ZNTLZentalis Pharmaceuti
Last close	$1.78close 2026-11-03
Change %	-3.78%close 2026-11-03
Market cap	$128Mclose 2026-11-03
P/E	loss, no P/E
Revenue	$0 ⊙ EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenueFromContractWithCustomerExcludingAssessedTax As ofFY ending 2025-12-31 Filing10-K · 0001725160-26-000014 · filed 2026-03-26 Open the filing on EDGAR →Open the XBRL payload → CiteZentalis Pharmaceuticals, Inc. (ZNTL), us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax: 0 USD, fiscal year ended 2025-12-31. Form 10-K, accession 0001725160-26-000014, filed 2026-03-26. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001725160/us-gaap/RevenueFromContractWithCustomerExcludingAssessedTax.json

Share this comparisonSend ZNTL side-by-side — free, straight from the filings.

Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.